Jump Financial LLC reduced its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,089 shares of the company's stock after selling 8,777 shares during the period. Jump Financial LLC owned about 0.11% of LivaNova worth $2,690,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after buying an additional 265,291 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after acquiring an additional 8,331 shares in the last quarter. Emerald Advisers LLC boosted its holdings in LivaNova by 8.2% in the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock valued at $34,850,000 after purchasing an additional 57,035 shares during the last quarter. Paradice Investment Management LLC boosted its holdings in LivaNova by 15.3% in the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after purchasing an additional 64,680 shares during the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in LivaNova during the 4th quarter valued at approximately $21,340,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
LIVN has been the subject of several research analyst reports. Barclays reduced their target price on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. Mizuho decreased their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Finally, Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $61.17.
View Our Latest Report on LivaNova
LivaNova Price Performance
LIVN opened at $35.58 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company's 50-day moving average price is $40.33 and its 200 day moving average price is $46.88. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $64.48. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of 84.71 and a beta of 0.90.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
See Also
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
